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Abstract 
Purpose of review – More than 80 loci are now reported to show robust genetic association 
with Systemic Lupus Erythematosus (SLE).  The differential functional effects of the risk 
alleles for the majority of these loci remain to be defined.  Here, we review current SLE 
association findings and the recent progress in the annotation of non-coding regions of the 
human genome as well as the new technologies and statistical methods that can be applied to 
further the understanding of SLE genetics. 
Recent findings – Genome-wide association studies (GWAS) have markedly expanded the 
catalogue of genetic signals contributing to SLE development; we can now explain more than 
50% of the disease’s heritability.  Expression quantitative trait loci (eQTL) mapping with co-
localisation analysis of GWAS results help to identify the underlying causal genes. The 
ENCODE, Roadmap Epigenome and the Blueprint Epigenome projects have jointly 
annotated more than 80% of the noncoding genome, providing a wealth of information (from 
healthy individuals) to define the functional elements within the risk loci.  Technologies, such 
as next-generation sequencing, chromatin structure determination and genome editing, will 
help elucidate the actual mechanisms that underpin SLE risk alleles. 
Review_Genetic advances in SLE-an update_LC-DLM-TJV
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Summary – Gene expression and epigenetic databases provide a valuable resource to 
interpret genetic association in SLE.  Expansion of such resources to include disease and 
multiple ancestries will further aid the exploration of the biology underlying the genetics. 
 
Keywords: Systemic lupus erythematosus; GWAS; expression quantitative trait loci; 
epigenome; causal variants 
 
Introduction  
Systemic lupus erythematosus (SLE) is a chronic inflammatory autoimmune disease 
associated with a wide range of signs and symptoms varying among affected individuals and 
can involve many organs and systems, including the skin, joints, kidneys, lungs, central 
nervous system, and hematopoietic system.  The population prevalence varies with ancestry, 
being more prevalent in non-European populations with a significant gender disparity 
towards women (9:1) during the years between menarche and menopause [1].   Although the 
exact etiology of lupus is not fully understood, a strong genetic link has been identified 
through the application of family and large-scale genome-wide association studies (GWAS).  
The concordance rate in monozygotic twins (24%) is approximately 10 fold higher than in 
dizygotic twins (2%) [2,3].  A recent study from Taiwan reported that the heritability was 
43.9% and the proportion of phenotypic variance explained by shared and non-shared 
environmental factors was 25.8% and 30.3%, respectively, suggesting non-heritable factors 
may play a considerable role in disease pathogenesis [4].   
There are now more than 80 loci reported to be associated with the susceptibility of SLE.  
Here, we review current SLE association findings and the recent progress in the annotation of 
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the non-coding region of the human genome as well as new technologies and statistical 
methods, in order to apply this knowledge to the understanding of SLE genetics. 
 
 
Insights from GWAS 
Genetic linkage analysis and candidate gene association studies identified several SLE 
susceptibility loci (e.g. HLA-DR2/DR3) [5].  Nevertheless, the advent and application of 
GWAS dramatically advanced knowledge of the genetic aetiology of SLE.   
There have been seven SLE GWAS in European population [6–12], six Asian GWAS [13–
18], subsequent meta-analysis and large-scale replication studies [19–22], published since 
2008.  Currently, 84 genetic loci are implicated as SLE risk (Figure 1: The CIRCOS plot [23] 
and supplementary Table 1), which, in order to avoid likely spurious associations, includes 
genetic associations with a P value less than 5  10-8 tested in a total sample size of at least 
1000 individuals.  The interactive version of a continually updated resource with details on 
SLE associations can be access through the following link: http://insidegen.com/insidegen-
LUPUS-Associations.html. 
With the caveat that the majority of mechanisms remain to be elucidated, it appears that the 
risk loci associated with SLE influence immune cell function.  Although functional studies 
are designed with a priori hypotheses in mind, key pathogenic pathways that are likely 
influenced by SLE-associated gene products include:  immune complex processing and 
phagocytosis; DNA degradation, apoptosis and clearance of cellular debris; neutrophil and 
monocytes signalling; Toll-like receptor and/or type I interferon signalling; nuclear factor 
kappaB activation; B and T-cell function and signalling.  Some genes associated with SLE 
may act through several pathways.  For example, TNFAIP3, encoding the ubiquitin-editing 
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enzyme A20, is a key regulator of nuclear factor-kappa-B (NF-kB)-derived pro-inflammatory 
responses, which is involved in both adaptive and innate immune pathways [24,25].  These 
SLE susceptibility loci contain predominantly common (frequency of > 0.1% in the general 
population) associated variants that have been confirmed among multiple ancestries, 
suggesting shared mechanisms in disease aetiology [26–28]. 
 
European GWAS 
The largest European GWAS of SLE conducted by our group [11], comprised 7,219 SLE 
cases and 15,991 controls of European decent, provided considerable power to detect disease 
risk loci.  Notably, the study identified 43 susceptibility loci, ten of which were novel loci: 
SPRED2, IKZF2, IL12A, TCF7-SKP1, DHCR7-NADSYN1, SH2B3, RAD51B, CIITA-SOCS1, 
PLD2, and CXorf21.  One of the great challenges posed by interpreting GWAS data is 
determining the causal genes implicated by the genetic association data.   As will be 
discussed and amplified below, we put some considerable effort into this process before 
naming the genes in the above list.  Irrespective of the underlying causal genes, we can 
conclude that the heritability explained by the risk alleles mapped at these loci is 15.3%, 
which is a large increase over the 8.7% reported by So et al [29] in 2011 using the same 
measure. 
 
Asian GWAS 
An extensive large-scale fine mapping study using Immunochip conducted in 4,478 SLE 
cases and 12,656 controls from six East Asian cohorts identified 10 novel loci [18] in Asians, 
encompassing GTF2IRD1-GTF2I, DEF6, IL12B, TCF7, TERT, CD226, PCNXL3, RASGRP1, 
SYNGR1, and SIGLEC6. Some of these were previously reported to be associated in 
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Europeans, for example, DEF6 and TCF7. The identification of these risk loci increased the 
explained heritability to 24% in Asian SLE. 
Trans ancestry meta analyses of GWAS 
A comparison of genetic association signals across the genome in European and Asian 
populations suggested that SLE susceptibility loci were shared extensively between both 
populations [21].  This motivated a trans ancestral approach at the genome-wide level to 
provide evidence of shared genetic components in the two populations and search for 
additional SLE associated loci.  The study by Morris and Sheng et al [21], that combined 
three GWAS from two ethnicities: Chinese (1659 cases and 3,398 controls) and European 
(4,044 cases + 6,959 controls), found evidence of considerable commonality in terms of SLE 
association signals as well as mapping novel susceptibility loci, including CD45, IKBKE, 
LBH, LPP-TPRG1-AS1, ATXN1, BACH2, GTF2I, JAK2, RNASEH2C, and ZFP90.   Notably, 
this study suggested that the increased prevalence of SLE in non-European (including Asians) 
has a genetic basis by comparison of genetic risk scores (GRS) between populations (Figure 
2) [21] .   Moreover, by using all genotyped SNPs (DNA chip) to calculate heritability 
explained, the explained variation (Vg) increase to 28% in Chinese subjects and 27% 
Europeans using the GCTA algorithm [30].  While there are still some uncertainties in the 
methodology for calculating heritability explained, this shows very strong evidence that we 
are making progress on the understanding of SLE heritability. 
The latest large-scale trans ancestral study using Immunochip [31], comprising three 
ancestries: European (EA: 6,748,cases and 11,516 controls), African-American (AA: 2,970 
case and 2,452 controls), and Hispanic Amerindian (HA: 1,872 cases and 2,016 controls), 
have identified nine novel loci for EA (TMEM39A-TIMMDC1, DGKQ, LRRC16A, SLC17A4, 
OLIG3-LOC100130476, GTF2IRD1-GTF2I , FAM86B3P, PKIA-ZC2HC1A, and GRB2 ), 
two for AA ( PTTG1-MIR146A and PLAT) and two for HA (GALC and CLEC16A ).  By 
comparing results across different populations, both ancestry-dependent and ancestry-
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
Page 6 of 23 
 
independent contributions to SLE risk are identified with the caveat of unequal cohort sizes.  
The study reveals evidence of sharing of genetic risk loci between ancestries as well as 
evidence that each individual population carries unique genetic risk factors at the locus level 
and at the allelic level. 
 
Missing heritability 
In summary, the chip heritability identified by the latest GWAS have explained around 28% 
of the disease heritability: a marked improvement on 8.3% calculated in 2011 [29].  
However, there is still one third of heritability left to explain, if we assume that the total 
estimated heritability is 43.9%.  Explanations for the missing heritability, including larger 
numbers of variants of smaller effect, rarer variants (possibly with larger effects) that are not 
present on genotyping arrays or structural variants poorly captured by existing arrays, as well 
as epigenetic modifications, have been suggested [32].  Innovations in genotyping and 
sequencing technologies, like the Immuno-chip platform [18,31] and next generation 
sequencing (NGS, as described below) will advance the investigation into common and rare 
variants and potential effects on the immune system, enhancing our understanding of the 
genetic risk of SLE. 
 
The LD that exists in the human genome facilitates the mapping of risk loci by reducing the 
number of genetic variants required for GWAS; however, the same correlation between 
genetic polymorphisms at these susceptibility loci then bedevils attempts to identify the 
actual causal allele(s) at risk loci. Bayesian fine mapping approaches had been proposed to 
derive smaller sets of SNPs (termed ‘credibility sets’) as the most likely causal variants at 
risk loci [33].  Nevertheless, statistical methods are inadequate to fully resolve the problem 
caused by LD.  In order to further pursue likely causal SNPs within any given credibility set, 
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the functional effect of SNPs can be studied in silico.  As the majority of variants within 
causal credibility sets are non-coding [34,35], function is inferred using gene transcript 
expression data and epigenetic modification data (as described below) (Figure 3 and Figure 
4). 
Application of eQTL mapping to GWAS results 
Assisted by dense genome coverage of the reference panel from the 1000 Genome project 
[36], imputation  and Bayesian inference provided evidence for missense variants 
underpinning association for eight genes, including PTPN22, FCGR2A, NCF2, IFIH1, 
WDFY4, ITGAM, PLD2, and TYK2  [11].  However, as mentioned above, the majority (85% 
~ 90%) of disease associated loci in SLE are located outside of protein-coding regions, 
suggesting that the underlying mechanism is likely regulatory, and so might exert their 
function through altering gene expression rather than by altering protein structure.  Of note, 
an over-representation (n=16) of transcription factors among the 43 SLE susceptibility genes 
have been annotated in our recent European GWAS [11], further indicating that perturbed 
gene regulation was a major functional risk factor for SLE.  Expression quantitative trait loci 
(eQTLs) mapping, which combines genome-wide expression profiling and genome-wide 
marker-based genotyping, takes advantage of the heritability of gene expression profiles to 
identify genetic variants that correlated with changes in gene expression.  eQTLs can be 
classified as “in cis” (locally) or “in trans” (at a distance) based on their physical distance 
from the regulated gene.   
 
Some studies [18,22] used public databases, such as the whole blood eQTL browser 
(http://genenetwork.nl/bloodeqtlbrowser/ )  [37] and tissue-specific GTEx portal 
( http://www.gtexportal.org/home/) [38], to determine whether the disease-associated SNP is 
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a significant eQTL.  Of note, there exists some limitations when applying eQTL analysis to 
the GTEx whole blood datasets, as in autoimmunity, we seek eQTLs in specific immune cell 
subsets.  In order to highlight the potential causal genes at the susceptibility loci robustly, it is 
essential to integrate the disease association and eQTL data using a co-localisation approach. 
That is, to establish that the same genetic variants that underlie the disease association also 
underlie the eQTL.  The presence of LD in the genome can readily obfuscate this overlap.  
Co-localisation methods, like the regulatory trait concordance (RTC) [39], conditional 
analysis [30], and Bayesian co-localisation [40], can be employed to infer that the disease 
association and eQTL have the same allelic basis.  As many variants have weak eQTL 
effects, erroneous conclusions will be made if analyses for co-localisation are not performed.  
An example of co-localisation analysis of eQTL and GWAS is shown in Figure 3.   
 
Recent studies by Morris et al [11,21] and Odhams et al [41] examined the functional 
outcome of SLE associated variants through the integration of GWAS and eQTL data from 
various cell types ex vivo, involving T cells, B cells, NK cells, stimulated and resting 
monocytes, as well as lymphoblastoid cell lines (LCL).  By integrating the results of eQTL 
and RTC analysis, they found evidence to support the role of causal genes as candidates at a 
given locus. For example, SOCS1 (Suppressor of Cytokine Signalling 1) was found to be a 
suggestive causal gene at the locus tagged by the SNP rs9652601 (with a RTC score higher 
than 0.9), rather than CLEC16A (C-Type Lectin Domain Family 16 Member A), even though 
the risk variant resides within the latter one - a gene previously reported as relating to other 
autoimmune diseases [42].  Moreover, the Odhams et al’s study [41] illustrated  the benefits 
of using RNA-seq as opposed to microarrays for eQTL mapping, due to more informative 
data generated by RNA-seq.  With RNA-seq, transcript profiling can be done on the gene-
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level, exon-level and splice-junction-level, which is more effective in explaining potential 
regulatory mechanisms.  
Nevertheless, we believe that many eQTLs related to SLE risk alleles remain unidentified, 
data from diverse stimulations and time points will be required, as well as gene expression 
data from patient material, to reveal the full eQTL landscape of SLE genetics.   
 
Epigenetics to annotate functional / regulatory variants  
An approach that is complementary to eQTL analyses, to examine the regulatory function of 
non-coding genetic variants, is to study gene regulation with epigenetics.  Epigenetic 
modifications, a term coined to describe genome-wide chromatin modification, including 
DNA methylation, histone modifications, chromatin accessibility, microRNA regulations, 
and 2D chromatin interactions [43], constitute an additional layer of genomic regulation, and 
may serve as a dynamic link between genotype and phenotype.  Such changes in DNA and 
chromatin structure correlate with changes in chromatin accessibility and transcription factor 
binding.   
The Encyclopedia of DNA elements (ENCODE) project (https://www.encodeproject.org/) 
[44] has systematically mapped regions of transcription, transcription factor association, 
chromatin structure and histone modification, and assigns biochemical functions for 80% of 
the genome, in particular outside of the protein-coding regions.  Overall, the project has 
provided an expansive resource to define the functional DNA elements for biomedical 
research, although the available cell types or cell lines are limited.  The cells of closest 
immune relevance in ENCODE Tier 1 and Tier 2 are LCLs (GM12878), B cells (CD20+) and 
monocytes (CD14+), as well as T cells (CD4+) and peripheral blood mononuclear cell 
(PBMC) in Tier 3.  A recent ImmunoChip study in Asians [18] took advantage of ENCODE 
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data to map the underlying loci.  For example, one of the signals (rs73366469) identified in 
this study was located between two ‘general transcription factor’ genes, GTF2I and 
GTF2IRD1.  By integrating the ENCODE data, they found that an indel SNP rs587608058 
(r2=0.81), ~1000bp from rs73366469, lay within conserved enhancer, active chromatin and 
transcription factor binding sites in LCLs and CD4+ T cells.  In addition, this region was 
found to overlap the transcription start sites for GTF2I and VCF through chromatin 
interacting analysis and chromosome confirmation capture (Hi-C) analysis, providing 
evidence for the potential causal variants and genes at this locus for further study.    
  
The Roadmap epigenomics project (http://www.roadmapepigenomics.org/ ) [46] integrated 
analysis of 111 reference human epigenomes to obtain a comprehensive map of the human 
epigenomic landscape across a large collection of primary cells, including immune cells, and 
tissues.  This map is extremely useful for studies of genome interpretation, gene regulation, 
cellular differentiation, genome evolution, genetic variation and human disease.  In our meta 
GWAS analysis of Chinese and European data [21], the histone modification markers, 
including acetylation markers (H3K27ac, H3K9ac) and methylation markers (H3K27me3 and 
H3K9me3), from blood cell types were used to investigate the potential regulatory function 
of the target risk loci.   For example, there are several genes, including SRGAP2, SRGAP2D, 
IKBKE, RASSF5, EIF2D and DYRK3, located within ±200kb of the lead GWAS SNP 
rs2297550.  The GWAS SNP was also found to be a putative eQTL for IKBKE, with the SLE 
risk allele correlated with reduced expression in CD4+ T cells [47], CD19+ B cells [48] and 
NK cells (data unpublished), but with increased expression in CD14+ monocytes [49].  
IKBKE encodes a noncanonical I-kappa-B kinase (IKK) that is essential in regulating 
inflammatory responses to viral infection by activating the type I interferon, NF-kB and 
STAT signalling pathways, suggesting IKBKE might be the potential causal gene.  Moreover, 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
Page 11 of 23 
 
there is an intense histone acetylation peak around the associated SNP rs2297550, indicating 
that rs2297550 may be a potential causal variant [21].  Figure 4 shows an example of fine 
mapping causal SNPs by integrating genetics and epigenetics. 
 
Another recent completed large-scale epigenomic project, the Blueprint project 
(http://www.blueprint-epigenome.eu/ ) [50–52], has impressively shown how epigenetic 
information and analyses can help to study the cellular mechanisms associated with complex 
human diseases.  Moreover, the Blueprint consortium generated three comprehensive 
reference panels, including genome (whole genome sequencing), transcriptome (RNA-seq), 
and epigenome (DNA methylation and histone modification), in three immune cells 
(Neutrophils, monocytes and T cells) from nearly 200 individuals to characterize the 
contributions of diverse genomic inputs to transcriptional variation.  Summary data from 
these panels can be accessed through http://blueprint-dev.bioinfo.cnio.es/WP10/ .   
High-resolution maps of promoter interactions [51] generated by ‘Promoter capture Hi-C’ 
(PChi-C) make it possible to study the long range regulatory in the three-dimensional nuclear 
space.  By integrating PCHi-C data with disease-associated SNPs generated by GWAS, we 
can prioritize the putative target genes for the risk loci.  The promoter interactomes map may 
serve as a more robust method to define cis-eQTLs rather than by distance, revealing insights 
into genomic regulatory mechanisms of diseases. 
 
Next generation sequencing (NGS) in the genome research 
With the development of NGS, high-throughput technologies that are now widely used in 
genome research, any part of the genome can be sequenced.  Based on the coverage of the 
genome, NGS strategies can be classified by scale: target region sequencing, whole-exome 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
Page 12 of 23 
 
sequencing (WES), and whole-genome sequencing (WGS).  Targeted resequencing of risk 
loci in disease cohorts may facilitate the identification of rare variants at common-allele-
associated loci [53]. WES captures all coding exons covering 1~2% of the genome.  
Nevertheless, as mentioned above, approximately 85~90% of the risk loci associated with 
SLE are located outside of the coding-regions. Compared to WES, WGS can capture the 
majority of the genome, which facilitates delineation of exon duplications and gene fusions, 
and non-coding regions that might be missing by WES.  However, the higher cost and time 
consuming bioinformatics analyses restrict the application of WGS [54].  In future, with the 
decreasing cost of sequencing and newly developed computation algorithms, WGS will be 
increasingly utilised.   
Incorporating with a wide range of chromatin profiling experiments, NGS is applied to 
investigate chromatin biology by identifying genomic loci that are occupied by nucleosomes, 
bound to transcription factors, or accessible to nuclease cleavage [55].  Technologies such as 
ChIP-seq [56], FAIRE-seq, DNase-seq [57,58], Hi-C [59], and ATAC-seq  [60]  enable 
genome-wide investigations of a broad range of chromatin phenomena in both qualitative and 
quantitative ways.  Moreover, when introducing NGS to the transcriptome level (RNA-seq), 
it can be used to detect changes in gene expression, as discussed earlier in this review 
[37,61,62]. 
  
 
Conclusion 
Linkage analysis and GWAS studies fail to fully explain disease heritability and do not 
address the causal nature of risk variants.  NGS continues to fuel the discovery of disease-
associated common and rare variants.  The advances in analysis tools, such as Bayesian fine 
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mapping approaches and high performance computation algorithms, help to make full use of 
the current massive data to uncover relationships and infer the causality among complex data.  
Comprehensive sets of functional annotations (ENCODE, Roadmap and Blueprint projects) 
in the context of complex genomic structure can be used to predict function and guide 
experimentation, such as precision genome editing with the CRISPR-Cas (Clustered 
regulatory interspaced short palindromic repeats/CRISPR-associated) [63,64], to address the 
long standing question of disease mechanism and heterogeneity.  Nonetheless, we still have 
not yet fully exploited analysis of GWAS data, such as 1) genetic studies in non-EU 
populations with different LD, especially important in SLE given the prevalence; 2) eQTL 
and epigenetic data in cells from non-EU populations for functional annotation; 3) epigenetic 
data in larger cohorts to look at inter-individual variation; 4) eQTL and epigenetic data from 
disease cohorts, to look for disease specific effects [65].  Studies based on these cohorts will 
advance our understanding of the disease mechanism, and ultimately speed up the arrival of 
the era of personalized medicine with genomic data incorporated into diagnosis, prognosis, 
and treatment in clinics.  
 
Key points 
1. The discovery of SLE-associated risk variants has accelerated in the past two years 
with huge sample size genome-wide and meta-analysis studies revealing novel loci in 
both coding and non-coding regions of the genome. 
2. eQTL mapping incorporating co-localisation analysis of GWAS results help to 
identify the underlying causal genes. 
3. The ENCODE, Roadmap and Blueprint projects which annotate non-coding regions 
have created comprehensive maps of the human genome. 
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4. SLE associated risk loci can be analysed bioinformatically, in the context of 
functional annotation to predict biological impact. 
5. Functional validation is required for designating variants as ‘causal variants’, and 
facilitated by the availability of genome editing tools such as CRISPR technology to 
artificially create the variant in a model system relevant for disease. 
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Figure titles and legends 
Supplementary Table 1. A summary of SLE risk loci. 
 
Figure 1. SLE risk loci in genomic context 
The CIRCOS plot [23] shows genes located within the SLE risk loci (84 in total) according to 
their genomic position. The full list of variants and locus genes for this plot is summarized in 
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supplementary Table 1.  The red block in each chromosome indicates the centromere of the 
chromosome.  Each chromosome arm is divided into cytogenetic bands of hg19.  
 
Figure 2. Box plots of GRS across the five major population groups. 
There are standard box plots showing medians, interquartile ranges and whiskers indicating 
1.5 times the interquartile range (Tukey box plots) [21].  EUR, European, N498; AMR, 
Amerindian, N=347; SAS, South Asian, N=487; EAS, East Asian, N=503; AFR, African, 
N=657; from the 1000 Genome phase 3 release.  The dashed line represents the increase in 
prevalence with the rank order (R1 represents the lowest prevalence, and R4 the highest). 
 
Figure 3. Overview of co-localisation analysis of GWAS and eQTL. 
This figure shows an example of eQTL analysis and the application of RTC for the causality 
inference.  Firstly, we subset the genes within the cis-window (+/- 1Mb) of the disease-
associated locus (rs2736340) and perform linear regression against the genotypes of the SNP.  
Co-localisation analysis of the GWAS signal and the eQTL signal was performed by 
calculating the RTC score.  SNP-expression pairs with RTC > 0.9 were considered causal.  
 
Figure 4.  Schematic overview of fine mapping causal SNPs by integrating genetics and 
epigenetics. 
This figure illustrates the functional annotation approach by an example, BLK (data 
unpublished).  The epigenetic data of two histone markers (H3K27ac and H3K9ac) from 
three primary cell types (B cell, T cell and monocytes) (Roadmap Project) are represented for 
the target locus.  This region contains 17 SNPs derived from 99% Bayesian credibility set of 
the risk locus. Rs2736340 is associated with SLE (Figure 3).  rs922483 overlaps H3K27ac in 
all three cell types while it overlaps the H3K9ac peak in B cells only. Furthermore, rs922483 
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is in strong linkage disequilibrium (LD) (r2 = 0.98) with rs2736340, indicating that there is 
transitive evidence due to the LD that rs922483 is also associated with SLE and is an eQTL.  
Therefore, rs922483 is the most likely functional SNP in this risk locus. 
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